Whole-genome single-nucleotide-polymorphism analysis for discrimination of Clostridium botulinum group I strains.

Appl Environ Microbiol

Division of Microbiology, Office of Regulatory Science, Center for Food Safety and Applied Nutrition, Food and Drug Administration, College Park, Maryland, USA.

Published: April 2014

Clostridium botulinum is a genetically diverse Gram-positive bacterium producing extremely potent neurotoxins (botulinum neurotoxins A through G [BoNT/A-G]). The complete genome sequences of three strains harboring only the BoNT/A1 nucleotide sequence are publicly available. Although these strains contain a toxin cluster (HA(+) OrfX(-)) associated with hemagglutinin genes, little is known about the genomes of subtype A1 strains (termed HA(-) OrfX(+)) that lack hemagglutinin genes in the toxin gene cluster. We sequenced the genomes of three BoNT/A1-producing C. botulinum strains: two strains with the HA(+) OrfX(-) cluster (69A and 32A) and one strain with the HA(-) OrfX(+) cluster (CDC297). Whole-genome phylogenic single-nucleotide-polymorphism (SNP) analysis of these strains along with other publicly available C. botulinum group I strains revealed five distinct lineages. Strains 69A and 32A clustered with the C. botulinum type A1 Hall group, and strain CDC297 clustered with the C. botulinum type Ba4 strain 657. This study reports the use of whole-genome SNP sequence analysis for discrimination of C. botulinum group I strains and demonstrates the utility of this analysis in quickly differentiating C. botulinum strains harboring identical toxin gene subtypes. This analysis further supports previous work showing that strains CDC297 and 657 likely evolved from a common ancestor and independently acquired separate BoNT/A1 toxin gene clusters at distinct genomic locations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993156PMC
http://dx.doi.org/10.1128/AEM.03934-13DOI Listing

Publication Analysis

Top Keywords

botulinum group
12
strains
12
group strains
12
toxin gene
12
botulinum
9
analysis discrimination
8
clostridium botulinum
8
strains harboring
8
ha+ orfx-
8
hemagglutinin genes
8

Similar Publications

Objective: Evaluation of the safety and effectiveness of Relatox, botulinum toxin type A in patients with focal spasticity (FS) of the upper limb as a result of a cerebrovascular accident (CVA) or traumatic brain injury (TBI).

Material And Methods: A multicenter, prospective, single-blinded, randomized, comparative clinical study included 210 patients of both sexes aged 18-75 years after moderate to severe TBI and CVA in seven sites in the Russian Federation. The patients were randomized into two groups.

View Article and Find Full Text PDF

We examined the effect of botulinum toxin-A on upper limb impairments and activity limitations in chronic stroke. This study is a secondary analysis of control group data from a national, multicenter, Phase III randomized trial with a masked outcome assessment. We studied 71 stroke survivors who received a botulinum toxin-A injection in any muscle(s) that crosses the wrist due to significant spasticity after a stroke greater than 3 months previously.

View Article and Find Full Text PDF

Importance: As average life expectancy increases, the role of beauty in quality of life (QOL) becomes more important. Invasive rejuvenation methods, such as cosmetic surgery and botulinum toxin injections, do not address the underlying causes of facial aging, are expensive, and carry inherent risks. Acupuncture, as a holistic alternative, may offer a safer method for facial rejuvenation by addressing the overall health of the body.

View Article and Find Full Text PDF

Optimal botulinum toxin therapy of dystonia in Germany: what would it cost?

J Neural Transm (Vienna)

December 2024

IAB - Interdiciplinary Working Group for Movement Disorders, Hamburg, Germany.

Botulinum toxin (BT) therapy is the therapy of choice for most forms of dystonia. We want to describe its costs, if all dystonia patients in Germany would have access to optimal BT therapy. For this, we combined the latest data on epidemiology of dystonia and dosing of BT therapy for dystonia.

View Article and Find Full Text PDF

Spasmodic dysphonia: the need for a combined neurological and phoniatric approach.

J Neural Transm (Vienna)

December 2024

IAB - Interdisciplinary Working Group for Movement Disorders, Hamburg, Germany.

Spasmodic dysphonia (SD) is now generally considered to be a task-specific focal dystonia. For the first time, we wanted to explore the relationship between SD and dystonia from a combined neurological and phoniatric perspective. For this, we studied 115 patients with non-psychogenic SD by a combined neurological and phoniatric evaluation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!